Literature DB >> 25932139

Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study.

Yujie Wu1, Boding Tong1, Yongheng Luo2, Guiyuan Xie3, Wei Xiong1.   

Abstract

OBJECTIVE: The effect of radiotherapy on moderate and severe Thyroid associated ophthalmopathy (TAO) was evaluated by various objective and quantitative indexes including T2 signal intensity ratios of orbital MRI inferior rectus and ipsilateral temporal muscle (T2SIR), extraocular muscles (EOM) volume, and the degree of exophthalmos using clinical research with prospective, randomized, double blind, self controlled.
METHODS: The patients with TAO who in the moderate and severe active period and had similar double eyes condition in the Outpatient Department of Ophthalmology of Xiangya No. 2 Hospital of Central South University from 2011.2 to 2014.2 were selected as objects in this study. The related body check was finished after the research group was built. For the object, one eye of patient having random radiotherapy was chosen as the experimental eye. The other eye in the same patient with pseudo radiotherapy (merely known by operator, doctors in department of ophthalmology and patients were double blind) was selected as the control eye. The radiotherapy plan was made by the operator according to the CT results. The T2 signal intensity ratios of orbital MRI inferior rectus and ipsilateral temporal muscle (T2SIR), extraocular muscles (EOM) volume, and the exophthalmos degree was compared by MRI check to evaluate the effect of radiotherapy.
RESULTS: The T2 signal intensity ratios of orbital MRI inferior rectus and ipsilateral temporal muscle (T2SIR), extraocular muscles (EOM) volume, and the exophthalmos degree between both eyes (experimental and control eyes) had significant differences and these data had statistical significance.
CONCLUSIONS: The treatment of radiotherapy is effective for the TAO in the moderate and severe active period.

Entities:  

Keywords:  EOM volume; Moderate and severe thyroid associated ophthalmopathy; T2SIR; exophthalmos degree; radiotherapy

Year:  2015        PMID: 25932139      PMCID: PMC4402786     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial.

Authors:  G J Kahaly; H P Rösler; S Pitz; G Hommel
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

4.  Modification of the classification of the eye changes of Graves' disease.

Authors:  S C Werner
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

5.  The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota.

Authors:  G B Bartley; V Fatourechi; E F Kadrmas; S J Jacobsen; D M Ilstrup; J A Garrity; C A Gorman
Journal:  Am J Ophthalmol       Date:  1995-10       Impact factor: 5.258

Review 6.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

7.  A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy.

Authors:  C A Gorman; J A Garrity; V Fatourechi; R S Bahn; I A Petersen; S L Stafford; J D Earle; G S Forbes; R W Kline; E J Bergstralh; K P Offord; D M Rademacher; N M Stanley; G B Bartley
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

8.  Long-term safety of orbital radiotherapy for Graves' ophthalmopathy.

Authors:  Claudio Marcocci; Luigi Bartalena; Roberto Rocchi; Michele Marinò; Francesca Menconi; Eugenia Morabito; Barbara Mazzi; Salvatore Mazzeo; Maria Sole Sartini; Marco Nardi; Francesco Cartei; Luca Cionini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

9.  A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.

Authors:  Mark F Prummel; Caroline B Terwee; Martin N Gerding; Lelio Baldeschi; Maarten P Mourits; Leo Blank; Friedo W Dekker; Wilmar M Wiersinga
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

10.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

View more
  6 in total

1.  Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.

Authors:  Ji Won Kim; Sun Hyup Han; Byeong Jae Son; Tyler Hyungtaek Rim; Ki Chang Keum; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-15       Impact factor: 3.117

Review 2.  Extraocular muscle enlargement.

Authors:  Khizar Rana; Valerie Juniat; Sandy Patel; Dinesh Selva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.535

3.  99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves' ophthalmopathy patients.

Authors:  Dan Liu; Xueliang Xu; Sha Wang; Chengzhi Jiang; Xinhui Li; Jia Tan; Zhihong Deng
Journal:  Int Ophthalmol       Date:  2019-12-02       Impact factor: 2.031

4.  Treatment of Graves' ophthalmopathy with an in-house Phosphorus-32 source: Initial clinical observations.

Authors:  Hai-Tao Hao; Yujun Wang; Xufu Wang; Sha Luan; Jianhua Cui; Yu Chen; Ya-Li Cui
Journal:  Exp Ther Med       Date:  2017-08-09       Impact factor: 2.447

5.  The Cerebellum Posterior Lobe Associates with the Exophthalmos of Primary Hyperthyroidism: A Resting-State fMRI Study.

Authors:  Wen-Feng Liu; Yong-Qiang Shu; Pei-Wen Zhu; Biao Li; Wen-Qing Shi; Qi Lin; Yu-Xin Liu; Meng-Yao Zhang; You-Lan Min; Qing Yuan; Yi Shao
Journal:  Int J Endocrinol       Date:  2019-11-28       Impact factor: 3.257

6.  Efficacy of orbital radiotherapy in moderate-to-severe active graves' orbitopathy including long-lasting disease: a retrospective analysis.

Authors:  Jin Hwa Choi; Jeong Kyu Lee
Journal:  Radiat Oncol       Date:  2020-09-21       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.